Characterize Your Biologics with Smart and Science-driven Concepts

How to choose the best panel of phase-appropriate analytical methods for complex modalities while maintaining aggressive development timelines
July 9, 2026
16:00 CEST
View Linkedin Event
OVERVIEW

Analytical characterization is key for the successful drug product development of biologics. Independent of the modality, the ability to understand the molecule in its formulation, including container closure system, its degradation pathways and critical quality attributes (cQAs) is central for the development of high-quality drug products for human applications. While modalities continue to diversify, the underlying analytical questions often remain remarkably consistent.

Across proteins, antibody-based therapeutics, viral vectors and other complex biologics, we repeatedly encounter similar analytical challenges: How do we reliably detect, identify and interpret particles? How can surfactants be characterized in a way that is sensitive, selective, and truly fit for purpose, beyond simple concentration measurements? These are not modality-specific problems, but fundamental questions rooted in formulation science.

 

At the same time, each modality brings its own complexity. For example, for AAV‑based products, the characterization of full versus empty capsids is not merely an analytical exercise, but a critical determinant of product quality, safety, and efficacy. Addressing such questions requires tailored approaches, built on solid scientific understanding rather than purely procedural method development.

 

At Coriolis, we deliberately chose not to reinvent analytical methods for every new project. Instead, we established the science‑driven Coriolis COR-Competences® platform analytical approaches built on 18-years of experience in drug product development, academic and applied research projects and continuous learning. This allows us to address recurring challenges efficiently while maintaining the flexibility needed for modality‑specific questions. Particle identification workflows and advanced surfactant characterization are just two examples where a deep understanding of the underlying science enables better decision‑making.

 

In this webinar, our experts will illustrate practical examples where standardized, yet scientifically sound approaches add value to the analytical characterization of biologics and discuss the science behind these selected methods. Join us to explore how strategic analytical focus can accelerate drug product development without compromising depth, quality or innovation

Addressed Challenges

01Selecting phase-appropriate analytical methods for complex biologics without slowing development timelines or compromising data quality.
02Identifying the optimal panel of analytical assays for a specific modality, from proteins and antibody-based therapeutics to viral vectors.
03Building a robust characterization package that meets regulatory expectations whilst supporting aggressive biologics development programmes.

WHAT YOU WILL LEARN

01Understand the central role of analytical characterization in biologics drug product development, from formulation to container closure systems.
02Recognise which analytical challenges are common across modalities and which require tailored, science-driven approaches for specific molecules.
03Discover how standardised, science-driven analytical platforms accelerate biologics drug product development without sacrificing depth or quality.
Reserve Your Seat
SPEAKERS
Dr. Andrea Hawe
Chief Scientific Officer at Coriolis Pharma
Dr. Andrea Hawe is the Chief Scientific Officer at Coriolis. She is an expert in drug product development for biologics with a strong scientific background in protein formulation, surfactant and particle characterization, and lyophilization process technology. Andrea has published more than 80 peer-reviewed papers and book chapters. At Coriolis, Andrea is responsible for Science & Technology in close collaboration with Dr. Tim Menzen. She also leads the Coriolis Scientific Advisory Board. Andrea values Coriolis for the opportunity to work with our clients worldwide on developing very exciting and novel biopharmaceutical drug products. She is also passionate about creating a positive and motivating working environment where each team member’s contribution is encouraged to shape Coriolis Pharma’s future. Her background is as a pharmacist with a PhD in Pharmaceutical Technology from the LMU Munich. After her PhD thesis, she continued her career as a postdoctoral scientist at the Leiden Academic Center for Drug Research (LACDR) in Leiden (The Netherlands). She was awarded a Veni grant (NWO, The Netherlands) to develop novel approaches for aggregate analysis. She joined Coriolis from the very beginning as a member of the founding team and has been supporting the company since 2008.
Read More
Biologics Characterization Webinar
Amber Raines, Ph.D
Senior Director of Client Project Management at Coriolis Pharma
Amber Raines, Ph.D. is Senior Director of Client Project Management at Coriolis Pharma, U.S., where she leads strategic client partnerships and project execution across biologics development programs. She is an expert at particle characterization and identification of (bio)pharmaceuticals, with a strong scientific background in biophysical characterization, formulation, and analytical development for protein therapeutics. Previously, she served as Senior Director of Rapid Analytics at KBI Biopharma, overseeing biophysical and particle characterization centers of excellence, innovation in analytical technologies, and collaborations with organizations such as NIST, NIH, and AAPS. Dr. Raines has over 15 years of industry experience at companies including Amgen and Merck. She holds a Ph.D. in Chemical and Biological Engineering from the University of Colorado Boulder and is an inventor on a U.S. patent related to reducing immunogenicity in therapeutic proteins.
Read More
Turn Registrants Into Relationships

Most registrants disappear after the session ends. We help you
open the right doors before, during, and after the webinar.

By ticking this box, you agree to the privacy policies of Coriolis Pharma and Livestorm, consenting to receiving communications related to this topic and other products or services within their portfolio